PTEN and prostate cancer: Interestingly, mTORC2, and more specifically RICTOR, is reported to be required for PTEN-deficient prostate tumorigenesis in mice [233], suggesting that targeting RICTOR/mTORC2 may be efficacious against PTEN-deficient prostate cancer in the clinic [233].